5q35 microduplication syndrome is a genetic condition caused by an extra segment on chromosome 5. People with 5q35 microduplication syndrome may have developmental delay, learning differences, and speech or motor delays. Some may also have distinctive facial features, feeding issues in infancy, short stature, or seizures, and not everyone will have the same experience. Features usually appear in infancy or early childhood and tend to be lifelong, but early supports can improve daily function. Care focuses on therapies, educational support, and treating specific issues like seizures or feeding problems, and the outlook varies by severity.
Overview
5q35 microduplication syndromeSymptoms
Features of 5q35 microduplication syndrome vary. Many children show developmental and speech delay, low muscle tone, and feeding difficulties in infancy, with short stature or small head size and distinctive facial features. Some have heart, kidney, or skeletal differences.
Outlook and prognosis
Many living with 5q35 microduplication syndrome grow and learn at their own pace, with strengths and challenges that vary widely. Early therapies for speech, movement, and learning often improve daily skills. Regular check-ins for growth, hearing, vision, and heart health guide long-term support.
Causes and risk factors
5q35 microduplication syndrome usually arises from a new (de novo) extra segment on chromosome 5q35. It can also be inherited from a parent with the duplication or a chromosomal rearrangement; no proven environmental or lifestyle risks—family history is main risk.
Genetic influences
Genetics are central in 5q35 microduplication syndrome, which stems from an extra copy of genes on chromosome 5q35. The size and gene content of the duplication influence severity and features. Most cases are de novo, though parental mosaicism or inheritance can occur.
Diagnosis
Doctors suspect 5q35 microduplication syndrome from clinical features, such as developmental differences and growth or facial patterns. Genetic tests, usually chromosomal microarray or targeted analysis, confirm the diagnosis. Prenatal ultrasound may support the genetic diagnosis of 5q35 microduplication syndrome.
Treatment and drugs
Treatment for 5q35 microduplication syndrome focuses on each person’s needs. Care often includes early developmental therapies, educational support, and targeted help for speech, movement, learning, or behavior; heart, vision, hearing, or feeding issues are managed by specialists. Regular check-ins guide adjustments as children grow.
Symptoms
Living with 5q35 microduplication syndrome often means a mix of developmental, growth, and learning differences that show up early in childhood. Early features of 5q35 microduplication syndrome can include slower weight gain, small head size, and delays in sitting, walking, or talking. Features vary from person to person and can change over time. Some children also have feeding issues, low muscle tone, or medical findings like heart or kidney differences.
In 5q35 microduplication syndrome, many children are smaller than expected for their age and gain weight slowly. Doctors may track height and weight closely and suggest nutrition support if needed.
Some children have a smaller head size on growth charts. Clinicians call this microcephaly, which means the head is smaller than average for age. This measurement alone does not define a child’s abilities.
Children with 5q35 microduplication syndrome may sit, crawl, and walk later than peers. Physical and occupational therapy can build strength, balance, and everyday skills.
Babies may feel a bit “floppy,” and joints can seem more flexible. This can affect posture, feeding, and stamina during play.
How people usually first notice 5q35 microduplication syndrome?
Many families first notice 5q35 microduplication syndrome when a baby has feeding difficulties, poor weight gain, or low muscle tone that makes the body feel “floppy,” and doctors may also pick up a small head size or unusual facial features during early checkups. In some, the first signs of 5q35 microduplication syndrome are developmental delays—such as sitting, standing, or talking later than peers—or learning differences that become clearer in toddlerhood or preschool. Occasionally, clues appear before birth on ultrasound, like growth restriction or structural differences, which prompt genetic testing to confirm how 5q35 microduplication is first noticed.
Types of 5q35 microduplication syndrome
5q35 microduplication syndrome can look different from one person to the next because the duplicated segment on chromosome 5 can vary in size and in which genes are included. Clinicians often describe them in these categories: focal duplications around a single key gene, larger duplications limited to the 5q35 band, and duplications that extend into neighboring regions. These variants of 5q35 microduplication can influence which features are most noticeable—such as growth differences, learning needs, or heart and skeletal findings. Understanding the main types of 5q35 microduplication syndrome can help make sense of how symptoms differ between them and guide expectations for follow-up.
RUNX2-focused duplication
The duplicated segment mainly involves the RUNX2 region. This type often links to extra or unusual ribs, collarbone differences, and distinctive skull or facial shape. Development and learning may be closer to typical compared with broader duplications.
NSD1-adjacent duplication
The duplication centers on 5q35.2–q35.3 near NSD1 without extending far beyond. People with this type may have milder growth effects but can show speech delay and variable learning differences. Facial features may be subtle and congenital anomalies are less frequent than in larger spans.
Isolated 5q35.3
The duplicated area is confined to the distal 5q35.3 segment. This can present with developmental delay, low muscle tone, and feeding challenges in infancy. Heart or kidney differences are less common but can occur depending on the exact genes included.
Broad 5q35 duplication
The duplicated segment spans most of 5q35 with multiple genes included. Features can be more wide ranging, including growth differences, congenital heart defects, skeletal changes, and more pronounced developmental delays. Not everyone will experience every type of feature.
Extended 5q35-plus
The duplication extends beyond 5q35 into neighboring chromosomal bands. Symptoms can be more variable and may include additional organ findings compared with types limited to 5q35. The broader gene content typically drives greater variability in features.
Mosaic duplication
Only a proportion of cells carry the 5q35 duplication. Symptoms don’t always look the same for everyone. People with mosaic changes may have milder or patchy features depending on how many cells and which tissues are affected.
Familial recurrent type
The same 5q35 duplication is inherited across family members. Features can cluster in a recognizable way within the family, though severity still varies. Knowing the specific inherited segment can clarify risks and the types of 5q35 microduplication seen in relatives.
What genetics can tell you about symptoms
Some people with 5q35 microduplication syndrome have extra copies of genes like NSD1, which can shift growth patterns, leading to short stature, small head size, and developmental delays. Duplications near brain-development genes may relate to learning differences, low muscle tone, and seizures in some.
Causes and risk factors
An extra copy of a small section of chromosome 5, known as 5q35, is the underlying cause.
It may be inherited from a parent or happen for the first time at conception.
Some risks are written in our DNA, passed down through families.
If a parent carries the duplication, each child has a 1 in 2 chance (50%) to inherit it, and the effects can vary widely.
The size and position of the duplicated segment, other genes, and life factors like nutrition and learning supports do not cause it, but they can shape early symptoms of 5q35 microduplication syndrome.
Environmental and biological risk factors
When families ask why 5q35 microduplication syndrome happens, the answer often traces back to how DNA is copied and packaged in eggs and sperm. Some biological risks are written in our genes, others arise through environment. If you’re weighing testing because of early symptoms of 5q35 microduplication syndrome, it helps to know what can raise the chance of this duplication starting in the first place. Here are biological and environmental factors that can influence risk.
The 5q35 area contains repeating DNA segments that can misalign when eggs or sperm form, creating an extra copy. This local DNA layout makes microduplications like those seen in 5q35 microduplication syndrome more likely to arise.
During the natural exchange of DNA between paired chromosomes in egg or sperm formation, occasional mistakes can add an extra copy at 5q35. These events are random and not caused by anything parents did.
Sometimes a duplication begins just after fertilization as the first cells divide. This can leave the change present in many or all cells of the developing embryo.
High doses of radiation to the ovaries or testes before conception can damage DNA in reproductive cells. This damage may increase the chance of new chromosomal changes, including duplications.
Genetic risk factors
Concerns like small head size or developmental delays—often the early symptoms of 5q35 microduplication syndrome—can lead to testing that looks for extra genetic material. This pattern happens when a tiny extra segment near the end of chromosome 5 (region q35) is present; this is known medically as 5q35 microduplication syndrome. People with the same risk factor can have very different experiences. Some duplications occur as a new change in a child, while others are inherited.
NSD1 gene dosage: Many people with 5q35 microduplication syndrome have an extra copy of the NSD1 gene. Extra NSD1 activity likely contributes to several core features by boosting growth-related signals beyond the usual level.
Duplication size matters: The extra segment can vary in size and exact position, changing which nearby genes are duplicated. Larger or differently placed duplications can influence how noticeable the condition is. This helps explain varied findings within 5q35 microduplication syndrome.
New in child: In many families, the duplication occurs for the first time in the child (de novo). When this happens, neither parent carries the same change in their blood cells. Testing both parents helps clarify recurrence risk.
Autosomal dominant inheritance: When a parent has the 5q35 microduplication, each child has a 50% chance of inheriting it. Effects can range from subtle to more apparent, even within the same family. Parent and child may be affected differently.
Parental mosaicism: Sometimes a parent carries the duplication in only a portion of their cells. This mosaic pattern, including in egg or sperm, can raise the chance of the duplication appearing again in a future pregnancy. Standard blood testing may miss very low-level mosaicism.
Parental rearrangement: Rarely, a parent has a balanced chromosomal rearrangement involving 5q35. This can increase the chance of an unbalanced duplication in a child. Chromosomal analysis in parents can check for this.
Repetitive DNA region: The 5q35 area contains repeated stretches of DNA that make the region prone to copy-number changes. During egg or sperm formation, these repeats can misalign, leading to an extra copy. This is a common mechanism behind microduplications.
Family history: A known family history of 5q35 microduplication syndrome raises the likelihood of the duplication appearing in relatives. Because effects vary, some relatives may be only mildly affected and unaware.
Lifestyle risk factors
5q35 microduplication syndrome is congenital and not caused by lifestyle choices, but daily habits can meaningfully influence symptoms, function, and long‑term complications. Thoughtful routines around diet, activity, sleep, and therapies can support growth, learning, and mobility. Below are practical ways that show how lifestyle affects 5q35 microduplication syndrome and highlight lifestyle risk factors for 5q35 microduplication syndrome.
Consistent, nutrient-dense meals help counter feeding difficulties, poor weight gain, and constipation common in this syndrome. Tailoring texture and pacing can reduce choking risk and improve energy for therapy and learning.
Adequate protein, healthy fats, and calcium/vitamin D support short stature and bone health. Avoiding excessive empty calories helps prevent excess weight that can strain joints, heart, and mobility.
Regular fluids and fiber ease constipation linked to hypotonia and limited mobility. Better bowel comfort can reduce behavioral distress and improve participation in school and therapy.
Daily, low-impact movement and therapy exercises improve muscle tone, coordination, and endurance. Better core strength can support posture and may help slow scoliosis progression and reduce falls.
Risk prevention
Because 5q35 microduplication syndrome is genetic, you can’t prevent the duplication itself, but you can lower the chance of complications and support healthier development. Planning ahead and staying on top of check‑ups often makes day‑to‑day life easier for families. Some prevention is universal, others are tailored to people with specific risks.
A genetics professional can explain recurrence risk for future pregnancies. They can also discuss options like prenatal testing and in‑vitro fertilization with embryo testing.
During pregnancy, screening and diagnostic tests can look for the duplication. Results can guide delivery planning and early specialist care.
Recognizing early symptoms of 5q35 microduplication syndrome can guide timely therapies and supports. Developmental, speech, and physical therapy started early may prevent avoidable delays.
Some people have heart or kidney differences that benefit from early detection. Regular echocardiograms or ultrasounds can catch issues before they cause problems.
Transmission
5q35 microduplication syndrome is not contagious; it cannot be caught or spread between people. The genetic transmission of 5q35 microduplication syndrome is usually autosomal dominant—if a parent carries the duplication, each child has a 50% chance of inheriting it, regardless of sex. Many cases happen as a new change in the egg or sperm (a “de novo” event), so parents’ genetic tests may be normal and the chance of it happening again is generally low, though a genetics team can give family-specific guidance. How 5q35 microduplication syndrome is inherited can vary because some parents who carry the duplication have very mild or no features, so testing both parents helps clarify recurrence risk for future pregnancies.
When to test your genes
5q35 microduplication syndrome is genetic, so testing is most useful when there’s a known family history, suggestive features in a child, or unexplained developmental, learning, or congenital differences. Consider testing before pregnancy or during prenatal care if a parent is affected or a prior child is diagnosed. Testing guides surveillance, therapies, and family planning.
Diagnosis
Families often seek answers when a child has developmental delays, learning differences, or growth concerns and a pattern starts to emerge. Early and accurate diagnosis can help you plan ahead with confidence. For this condition, doctors focus on clinical clues and confirm the findings with genetic tests—the steps involved in the genetic diagnosis of 5q35 microduplication syndrome.
Doctors look at growth, head size, facial traits, muscle tone, and development. These clinical features can point toward a chromosome copy change and guide which tests to order.
Providers review milestones, learning, speech, and feeding to look for consistent patterns. This context helps match features to known syndromes and prioritize genetic tests.
A detailed family and health history can help identify inherited patterns and guide next steps. It may also show who else in the family could benefit from testing.
This first-line test checks for extra or missing pieces of DNA across the genome. It can detect a duplication at 5q35 and estimate its size.
Stages of 5q35 microduplication syndrome
5q35 microduplication syndrome does not have defined progression stages. This condition varies from person to person, and many features are present from birth or early childhood rather than unfolding in a predictable, stepwise way. Doctors usually confirm the diagnosis with a clinical genetics evaluation and lab testing such as chromosomal microarray; genetic testing may be offered to clarify certain risks. Clinicians then monitor growth, development, and any specific needs over time, often considering early symptoms of 5q35 microduplication syndrome alongside results from hearing, vision, heart, or kidney checks.
Outlook and prognosis
Looking ahead can feel daunting, but most children with 5q35 microduplication syndrome make steady gains with therapy and school supports. The range is wide: some children walk and talk on a typical timeline, while others need extra time and ongoing services for speech, learning, or coordination. Seizures, if they occur, are often manageable with medication, and heart or kidney differences—when present—are closely watched by specialists.
The outlook is not the same for everyone, but many people with 5q35 microduplication syndrome have a normal life span, especially when major organ differences are mild or well treated. Developmental challenges tend to be the most persistent issue into adulthood, shaping education and job support needs rather than limiting life expectancy. Early symptoms of 5q35 microduplication syndrome can be subtle—low muscle tone, feeding trouble, or delays—and starting therapies early is linked with better long-term skills.
Prognosis refers to how a condition tends to change or stabilize over time. In 5q35 microduplication syndrome, skills usually improve over the years, with plateaus and spurts rather than sudden losses. Serious complications are uncommon but can stem from untreated heart defects, hard‑to‑control seizures, or breathing issues; with routine care, the risk of life‑threatening events remains low. Talk with your doctor about what your personal outlook might look like, including which evaluations (heart, kidneys, vision, hearing) are recommended now and how often to follow up as needs change.
Long-term effects
5q35 microduplication syndrome can affect growth, learning, and health from childhood into adult life. Early symptoms of 5q35 microduplication syndrome often appear in infancy, and some features continue, though their impact can change with age. Long-term effects vary widely, with some people having mild traits and others needing substantial support. Many live into adulthood, and overall outlook often depends on whether there are major heart, brain, or kidney differences.
Shorter height and a smaller head size can persist from childhood into adulthood. Some also have a smaller build and lower weight than peers.
Mild to moderate learning differences are common and can shape school progress and adult independence. Daily living skills may improve over time but often remain uneven.
Speech can be delayed, with clearer understanding than expression for many. Pronunciation and finding words may remain challenging into adulthood.
Low muscle tone and delayed milestones in childhood can evolve into ongoing clumsiness or poor coordination. Fine motor tasks like handwriting or buttons may stay effortful.
How is it to live with 5q35 microduplication syndrome?
Living with 5q35 microduplication syndrome often means navigating developmental differences that can touch speech, learning, and coordination, with medical check-ins to watch growth, muscle tone, and sometimes heart or skeletal features. Daily life may involve therapies—speech, occupational, physical—and school supports, which can be time‑consuming but also build skills and confidence over time. Families and caregivers often become skilled advocates, coordinating care and celebrating steady gains, while friends and classmates may need simple, clear explanations to foster inclusion and patience. Many find that predictable routines, visual aids, and a team of supportive professionals make everyday activities smoother and help each person’s strengths shine.
Treatment and drugs
Treatment for 5q35 microduplication syndrome focuses on easing symptoms, supporting development, and preventing complications over time. Because features can vary widely, care is usually coordinated by a pediatrician or primary doctor with referrals to specialists such as cardiology, neurology, physical and speech therapy, ophthalmology, and ENT, depending on each person’s needs. Early therapies—like physical, occupational, and speech therapy—can help with motor skills, feeding, and communication, while educational supports and behavioral therapy address learning and behavior differences; medicines may be used for issues such as seizures, attention, mood, reflux, or sleep when needed. Surgery or procedures may be recommended for specific problems (for example, heart defects, cleft palate, significant ear, nose, and throat concerns, or spine issues), and regular follow-up checks help track growth, hearing, vision, and development. Not every treatment works the same way for every person, so keeping a shared plan with your care team—and updating it as needs change—can make day-to-day life with 5q35 microduplication syndrome more manageable.
Non-drug treatment
Day-to-day care for 5q35 microduplication syndrome focuses on building skills, supporting communication, and making feeding, movement, and learning easier. Non-drug treatments often lay the foundation for progress, from infancy through school years. Plans are tailored to each person’s strengths and challenges and may change as needs evolve. Coordinated support across therapies usually works best.
Therapy in the first years can boost motor, language, and social development. Teams help spot early symptoms of 5q35 microduplication syndrome and guide parents on home practice. Services may include home-based visits and parent coaching.
Guided exercises can improve muscle tone, balance, and coordination. Therapists teach safe ways to build strength for sitting, standing, and walking. Bracing or mobility aids may be recommended if needed.
Practice with hand skills and daily routines can increase independence. Therapists work on dressing, play skills, and sensory challenges. Home strategies help carry progress into everyday life.
Sessions support understanding, speech sounds, and expressive language. Therapists tailor activities to the child’s level and may involve parents in each step. Feeding and oral-motor skills can be addressed if needed.
Your genes may have an impact on how drugs work for you
Medicines can work differently in people with 5q35 microduplication syndrome because extra copies of genes in this region may change how the body processes drugs or responds to them. Pharmacogenetic testing and careful dose adjustments can help tailor safer, more effective treatment.
Pharmacological treatments
Living with 5q35 microduplication syndrome often means managing seizures, reflux or feeding problems, attention or behavior challenges, and sleep issues. Medicines are used to treat specific symptoms and to support comfort and development. Not everyone responds to the same medication in the same way. Treatments are tailored to the early symptoms of 5q35 microduplication syndrome and adjusted as needs change.
Levetiracetam, valproate, and oxcarbazepine are commonly used to prevent seizures. Doctors may also consider lamotrigine or topiramate based on seizure type. Dosing may be increased or lowered gradually to balance control and side effects.
Omeprazole or lansoprazole can reduce stomach acid and ease reflux-related discomfort. Famotidine is another option if proton-pump inhibitors are not suitable. This can improve feeding comfort and weight gain.
Polyethylene glycol (PEG) softens stools and helps regularity. Senna or bisacodyl may be used short term if stools are very hard. Alongside drug therapy, fluids and fiber remain important.
Methylphenidate or amphetamine stimulants can improve attention and reduce hyperactivity. Guanfacine or clonidine may help if tics, sleep issues, or appetite loss occur with stimulants. If one option isn’t effective, second-line or alternative drugs may be offered.
Genetic influences
In 5q35 microduplication syndrome, there is an extra copy of a small piece of chromosome 5 (the q35 region), which changes the balance of several nearby genes. This duplication can happen as a new event in a child or be inherited from a parent; if a parent has it, each pregnancy has about a 1 in 2 (50%) chance of passing it on. Effects can vary widely because the added genetic material can act a bit like a dimmer switch, turning some gene activity up more in one person than another. That’s why some parents with the same duplication have very mild or even unnoticed features, while their child may have more apparent learning or growth differences. DNA testing can sometimes identify these changes. When early symptoms of 5q35 microduplication syndrome prompt evaluation, confirming the duplication can guide care and inform options for future pregnancies, even when the change arose as a one-time event.
Is 5q35 microduplication syndrome genetic?
Genetics are central in 5q35 microduplication syndrome, which stems from an extra copy of genes on chromosome 5q35. The size and gene content of the duplication influence severity and features. Most cases are de novo, though parental mosaicism or inheritance can occur.
Pharmacogenetics—how genetics influence drug effects
Treatment in 5q35 microduplication syndrome is usually symptom-focused—there isn’t a single medicine that targets the duplication itself. People may use medicines for seizures, reflux, behavior, sleep, or mood, and response can vary with age, body size, other health conditions, and individual biology. Alongside medical history and current medicines, genetic testing can help doctors tailor the dose of certain drugs when they’re needed. There aren’t drug–gene guidelines unique to 5q35 microduplication syndrome, but results from standard panels (for example, genes that affect how quickly you process some antidepressants or antiseizure medicines) can sometimes guide choices and dosing. Because many living with 5q35 microduplication syndrome have smaller body size or feeding challenges, clinicians often adjust doses carefully and watch for medication side effects in 5q35 microduplication syndrome. Care teams typically review all medicines for interactions and use a start‑low, go‑slow approach to find the lowest effective dose with the fewest side effects.
Interactions with other conditions
Day to day, families often juggle 5q35 microduplication syndrome alongside other health issues that influence learning, energy, and growth. Doctors call it a “comorbidity” when two conditions occur together, and in this syndrome that may include epilepsy, autism spectrum features or ADHD, feeding difficulties with reflux, and sometimes congenital heart defects. When seizures are present, they can affect attention and school readiness; if sleep apnea or significant reflux occurs, fatigue and irritability may amplify developmental and behavioral challenges. Early symptoms of 5q35 microduplication syndrome—such as poor feeding or low muscle tone—can also overlap with conditions like gastroesophageal reflux or respiratory infections, making it harder to sort out what’s driving a bad week.
Medication plans may need careful coordination; for example, anti‑seizure drugs, treatments for attention or anxiety, and therapies for reflux can interact or have side effects that affect progress in therapy. Interactions can look very different from person to person, especially when heart, vision, or hearing problems are also part of the picture. With careful care, many people live well despite having both 5q35 microduplication syndrome and another condition, especially when pediatricians, neurologists, cardiologists, and therapists share information. Talk with your doctor about how your conditions may influence each other so supports at school, home, and clinic stay aligned.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described babies with small heads, short height, and learning differences that seemed to run in families. Relatives might recall an uncle who was shorter than his siblings, or a child who needed extra time in school, with subtle facial features that “looked like Grandma’s side.” These patterns were noticed long before anyone could see chromosomes, much less small changes within them.
From early theories to modern research, the story of 5q35 microduplication syndrome reflects how tools shape understanding. In the mid‑20th century, doctors first linked some developmental conditions to large gains or losses of chromosomes. As laboratory methods improved, smaller changes—tiny “extra copies” of DNA—came into view. By the 1990s and 2000s, high‑resolution chromosome tests and array technologies allowed clinicians to detect microduplications at the end of chromosome 5, in a region called 5q35.
Initially understood only through symptoms, later studies connected shared features—such as developmental delays, smaller head size, feeding challenges in infancy, and sometimes heart or skeletal differences—to extra genetic material in 5q35. Reports gathered children and adults with overlapping findings, showing that even when features varied, many had the same duplicated stretch of DNA. This helped move the condition from isolated case reports to a recognized microduplication syndrome.
Once considered rare, now recognized as a spectrum, 5q35 microduplication syndrome shows wide variation. Some people have mild learning differences and live independently; others need more day‑to‑day support. Early descriptions focused on children seen in specialty clinics, which likely skewed toward more noticeable symptoms. As genetic testing became more available, especially during pregnancy or after developmental assessments, clinicians began identifying individuals with subtler signs—and sometimes parents who carried the same microduplication with few or no symptoms. This broader view clarified that the size and exact location of the duplicated segment can influence how the condition appears.
Advances in genetics also refined inheritance counseling. Families and communities once noticed patterns without a clear explanation. Today, we know that 5q35 microduplication syndrome can be inherited from a parent or occur as a new change in a child. Documenting both scenarios helped clinicians estimate recurrence risks and guide testing of relatives when appropriate.
With each decade, the history of 5q35 microduplication syndrome has moved from bedside observation to precise genetic mapping. Understanding this path explains why older records may use different names or emphasize different features. It also reminds us that many living with the condition were missed in the past. Knowing the condition’s history supports more accurate diagnosis, earlier support for developmental needs, and informed family discussions going forward.